Pharming Group's EBIT per Share for the
three
months ended in Mar. 2026 was $-0.03.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.44.
During the past 12 months, the average EBIT per Share Growth Rate of Pharming Group was 2400.00% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 22.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Pharming Group's EBIT per Share or its related term are showing as below:
PHAR'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -47.7 Med: 28.9 Max: 83.1
Current: 22.7
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Pharming Group was 83.10% per year. The lowest was -47.70% per year. And the median was 28.90% per year.
PHAR's 3-Year EBIT Growth Rate is ranked better than 60.36% of 1178
companies
in the Biotechnology industry
Industry Median: 15.55
vs PHAR: 22.70
Pharming Group's EBIT for the
three
months ended in Mar. 2026 was $-2.1 Mil.
Pharming Group (NAS:PHAR) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Pharming Group EBIT per Share Related Terms
Pharming Group EBIT per Share Historical Data
* Premium members only.
The historical data trend for Pharming Group's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.44
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharming Group (PHAR) has a EBIT per Share of $0.44 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Pharming Group and its competitors. According to the industry distribution chart, Pharming Group ranks #467 out of 1178 companies in the Biotechnology industry, placing it in the top 39.6%.
Is Pharming Group's EBIT per Share too high?
Pharming Group's current EBIT per Share is $0.44. The Biotechnology industry median EBIT per Share is 15.55. Pharming Group's value of $0.44 is 97.2% below this industry median. Based on the distribution chart, Pharming Group ranks #467 out of 1178 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Pharming Group has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pharming Group's EBIT per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharming Group ranks #467 out of 1178 companies for EBIT per Share. This puts Pharming Group in the upper half of its industry. The industry median EBIT per Share is 15.55. Pharming Group's value of $0.44 is 97.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.55, based on 1,178 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharming Group's current EBIT per Share of $0.44 is 97.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Pharming Group and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharming Group's current EBIT per Share is $0.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharming Group stock overvalued right now?
Based on GuruFocus' analysis, Pharming Group (PHAR) is currently considered Fairly Valued. The stock's GF Value™ is $14.25, compared to a current price of $13.77 — trading 3.4% below its estimated fair value. The current EBIT per Share is $0.44 and 97.2% below the Biotechnology industry median of 15.55. Pharming Group's overall GF Score™ is 77/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Pharming Group (PHAR), the current EBIT per Share is $0.44 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharming Group (PHAR) Overvalued in 2026?
Based on GuruFocus' analysis, Pharming Group stock appears to be undervalued.
The current stock price of $13.77 is trading 3.4% below its estimated GF Value™ of $14.25.
GuruFocus considers Pharming Group to be Fairly Valued.
Key valuation signals for PHAR:
EBIT per Share: $0.44
GF Value™: $14.25 vs. price of $13.77 (3.4% below fair value)
Industry Position: 97.2% below the Biotechnology median (#467 of 1178)
No single metric tells the full story. See the PHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.
77GF Score
Get the complete analysis for PHAR
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PHAR has been successfully added to your 
